Biotech Movers

Updated May 31, 2026

Stocks with the most signal activity right now: fund position changes, insider purchases, and upcoming catalysts from 20 specialist biotech hedge funds. Ranked by composite activity score.

How the activity score works

What counts as a mover?

Any biotech stock with recent signal activity: new or changed fund positions from the latest 13F filings, insider purchases in the last 30 days, or an upcoming catalyst within 90 days. Stocks are ranked by an activity score that weights these signals.

How often is this updated?

This page refreshes every hour. Fund position data updates quarterly after 13F filing deadlines. Insider signals are ingested daily from SEC EDGAR Form 4 filings. Catalyst dates are refreshed weekly.

What does the activity score mean?

The activity score combines the number of funds with recent position changes, insider buying activity and dollar volume, catalyst proximity, and fund convergence. Higher scores indicate more concurrent signal activity around a stock.

Are exits and trims included?

Yes. Fund exits and trims appear in the table because they are actionable signals. A multi-fund exit from a stock is just as informative as a multi-fund accumulation.

429 active tickers0 with insider buys35 catalysts in 30d

Ticker	Fund Signal	Funds↕	Insider Buys↕	Next Catalyst↕	Score?↓
PCVX Vaxcyte Inc.	Exited Baker Bros. Advisors, Perceptive Advisors +9	3	—	245d Ph3	185
RNA Avidity Biosciences Inc.	Exited RA Capital Management, Commodore Capital +6	4	—	92d Ph3	140
AKRO Akero Therapeutics Inc.	Exited Perceptive Advisors, Rock Springs Capital +5	4	—	—	120
DYN Dyne Therapeutics Inc.	Exited RTW Investments, Rock Springs Capital +6	1	—	—	120
CMPS COMPASS Pathways plc	Trimmed Driehaus Capital, Cormorant Asset Management +4	2	—	30d Ph3	110
CGON CG Oncology, Inc.	Exited RA Capital Management, BVF Partners +3	3	—	30d Ph2	110
SYRE Spyre Therapeutics, Inc.	Trimmed Commodore Capital, Rock Springs Capital +4	2	—	30d Ph2	110
OLMA Olema Pharmaceuticals, Inc.	Exited Perceptive Advisors, Avoro Capital Advisors +4	2	—	30d Ph3	110
OCUL Ocular Therapeutix Inc.	Exited Perceptive Advisors, Rock Springs Capital +5	—	—	222d Ph3	110
GPCR Structure Therapeutics Inc.	Trimmed Rock Springs Capital, Driehaus Capital +4	6	—	92d Ph2	110
DSGN Design Therapeutics, Inc.	Exited EcoR1 Capital, Baker Bros. Advisors +4	3	—	110d Ph3	110
ALNY Alnylam Pharmaceuticals Inc.	Exited Avoro Capital Advisors, Deep Track Capital +4	4	—	331d Ph2	110
KURA Kura Oncology, Inc.	Exited EcoR1 Capital, Perceptive Advisors +5	1	—	—	105
CYTK Cytokinetics Incorporated	Exited Driehaus Capital, Perceptive Advisors +5	2	—	—	105
ABOS Acumen Pharmaceuticals, Inc.	Added RA Capital Management, Rock Springs Capital +4	1	—	153d Ph2	105
PRAX Praxis Precision Medicines, Inc.	Added Driehaus Capital, Cormorant Asset Management +2	3	—	30d Ph3	105
JANX Janux Therapeutics Inc.	Added Rock Springs Capital, EcoR1 Capital +4	2	—	—	100
VRNA Verona Pharma plc	Exited Baker Bros. Advisors, Perceptive Advisors +4	2	—	66d Ph2	95
FDMT 4D Molecular Therapeutics, Inc.	Exited Baker Bros. Advisors, RA Capital Management +2	3	—	30d Ph2	95
MGNX MACROGENICS INC	Exited Perceptive Advisors, Baker Bros. Advisors +4	2	—	273d Ph2	95
CNTA Centessa Pharmaceuticals plc	Trimmed Cormorant Asset Management, Rock Springs Capital +4	2	—	214d Ph2	95
IPSC Century Therapeutics, Inc.	New Rock Springs Capital, Commodore Capital +3	1	—	—	95
EXAS Exact Sciences Corporation	Exited Driehaus Capital, Rock Springs Capital +3	3	—	198d Ph2	95
IVVD Invivyd, Inc.	Exited Deep Track Capital, Redmile Group +4	—	—	92d Ph3	95
EWTX Edgewise Therapeutics, Inc.	Exited EcoR1 Capital, Deep Track Capital +2	4	—	30d Ph2	95
RVMD Revolution Medicines Inc.	Added Baker Bros. Advisors, OrbiMed Advisors +1	3	—	30d Ph3	90
NMRA Neumora Therapeutics, Inc.	Exited OrbiMed Advisors, Rock Springs Capital +4	2	—	—	90
NUVL Nuvalent Inc.	Exited Baker Bros. Advisors, Driehaus Capital +3	3	—	—	90
AUTL Autolus Therapeutics plc	Exited Perceptive Advisors, Rock Springs Capital +4	2	—	—	90
ETNB 89bio Inc.	Exited Rock Springs Capital, RA Capital Management +3	5	—	—	90
FATE Fate Therapeutics Inc.	Exited EcoR1 Capital, OrbiMed Advisors +3	4	—	—	90
ITOS iTeos Therapeutics SA	Exited EcoR1 Capital, OrbiMed Advisors +3	3	—	—	90
TNGX Tango Therapeutics Inc.	Exited Commodore Capital, Deep Track Capital +3	4	—	—	90
IDYA IDEAYA Biosciences Inc.	Added Baker Bros. Advisors, Cormorant Asset Management +1	4	—	22d Ph2	90
ELVN Enliven Therapeutics, Inc.	Added Rock Springs Capital, RA Capital Management +2	3	—	—	85
ORKA Oruka Therapeutics, Inc.	New Rock Springs Capital, Perceptive Advisors +2	—	—	395d Ph2	85
RYTM Rhythm Pharmaceuticals Inc.	Held Rock Springs Capital, Driehaus Capital +2	5	—	153d Ph2	80
RCKT Rocket Pharmaceuticals Inc.	Exited EcoR1 Capital, Baker Bros. Advisors +2	3	—	184d Ph3	80
TVTX Travere Therapeutics Inc.	Exited OrbiMed Advisors, Driehaus Capital +2	1	—	30d Ph2	80
NTRA Natera Inc.	Exited Baker Bros. Advisors, Driehaus Capital +3	1	—	214d Ph3	80
ARGX argenx SE	Exited EcoR1 Capital, Perceptive Advisors +3	2	—	61d Ph2	80
VKTX Viking Therapeutics Inc.	Exited Baker Bros. Advisors, Perceptive Advisors +3	2	—	396d Ph3	80
VERA Vera Therapeutics Inc.	Exited Driehaus Capital, Rock Springs Capital +3	1	—	122d Ph2	80
XENE Xenon Pharmaceuticals Inc.	Exited Perceptive Advisors, Rock Springs Capital +3	2	—	92d Ph3	80
INSM Insmed Incorporated	Exited Perceptive Advisors, Deep Track Capital +2	4	—	214d Ph3	80
SPRY ARS Pharmaceuticals, Inc.	Exited Driehaus Capital, Cormorant Asset Management +2	2	—	30d Ph2	80
TARS Tarsus Pharmaceuticals Inc.	Exited Perceptive Advisors, Rock Springs Capital +3	1	—	214d Ph2	80
ACLX Arcellx Inc.	Exited Perceptive Advisors, Baker Bros. Advisors +2	3	—	214d Ph2	80
MLTX MoonLake Immunotherapeutics	Exited OrbiMed Advisors, EcoR1 Capital +3	2	—	120d Ph3	80
IONS Ionis Pharmaceuticals Inc.	Exited EcoR1 Capital, Deep Track Capital +2	2	—	30d Ph3	80

Showing 50 of 429

Get movers before the market opens

Fund moves, insider buys, and catalyst alerts — delivered free every Monday.

See why PCVX is active — and what comes next

AI context on every fund move, insider trade, and catalyst. Full access for 14 days. Card required, no charge until day 15. Cancel anytime.

Start 14-Day Free Trial

Drill into any signal

Fund Convergence

See which stocks multiple specialist funds are buying at once

Catalyst Calendar

Every PDUFA date, Phase 3 readout, and AdCom in one view

Insider Trading

When executives buy their own stock — the strongest bullish signal

Cash Runway

Which biotechs are running low on cash and face dilution risk

Short Squeeze

High short interest + fund buying + upcoming catalyst = squeeze setup

Signal Rankings

Every signal in one composite score — ranked by conviction

13F Changes

What top biotech funds bought and sold in the latest 13F filing

Want AI context on every signal? Start free trial →